Platin desensitizations in thoracic malignancies and risk factors for breakthrough reactions

Main Article Content

Gözde Köycü Buhari
İlkay Koca Kalkan
Hale Ateş
Sakine Nazik Bahçecioğlu
Şenay Demir
Selma Yeşilkaya
Gürgün Tuğçe Vural Solak
Kurtuluş Aksu
Ferda Öner Erkekol


breakthrough reaction, chemotherapy, desensitization, hypersensitivity reaction, platin


Although platin desensitization is a safe and effective alternative for patients with hypersensitivity reactions (HSRs), sometimes breakthrough reactions (BTRs) can be encountered. However, data about the risk factors for BTRs are limited. The aim of this study is to define the outcomes of desensitization, the characteristics of BTRs, and to identify the risk factors for BTRs with platins in thoracic malignancies. This is a retrospective report of patients with thoracic malignancies who underwent platin desensitization. Patients’ demographics, initial HSR characteristics, skin test results, desensitization outcomes, and BTR characteristics were recorded. Thirty-three lung cancer and 14 malignant pleural mesothelioma (MPM) patients were included in the study. The culprit drug was cisplatin in 29 and was carboplatin in 18 patients. Skin test positivity was 43.5% with cisplatin, 50% with carboplatin, and it was found to be higher if the interval between the initial HSR and skin testing (ST) was ˃20 days (p = 0.027). One hundred and five desensitization courses were performed. Twenty-two patients had 33 BTRs. Skin test positivity was higher in the BTR-positive group (p = 0.025). BTRs (18.2%; n = 6) were more severe than initial HSR. In the case of epinephrine administration during initial HSR, epinephrine administration during the first BTR was found to be more (p = 0.036). The target dose was achieved in 92.4% of desensitization courses. The number of previous platin infusions ≥10 was found to be an independent risk factor for BTR development (p = 0.036 OR:17.641, 95% CI: 1.211–256.971). Identification of risk factors for BTR will guide appropriate management and desensitization approaches for platin HSRs.

Abstract 136 | PDF Downloads 129 HTML Downloads 15 XML Downloads 4


1. Castells M, Sancho-Serra Mdel C, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother. 2012;61(9):1575–1584. 10.1007/s00262-012-1273-x

2. Castells MC. Hypersensitivity to antineoplastic agents. Curr Pharm Des. 2008;14(27):2892–2901. 10.2174/138161208786369803

3. Vervloet D, Durham S. Adverse reactions to drugs. BMJ. 1998;316(7143):1511–1514. 10.1136/bmj.316.7143.1511

4. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol. 1994;53(1):121–122. 10.1006/gyno.1994.1098

5. Castells M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol. 2006;6(4):271–277. 10.1097/01.all.0000235900.57182.15

6. Alen Coutinho I, Costa Sousa F, Cunha F, Frutuoso C, Ribeiro C, Loureiro C, et al. Key elements in hypersensitivity reactions to chemotherapy: experience with rapid drug desensitization in gynaecological cancer in a tertiary hospital. Eur Ann Allergy Clin Immunol. 2022;54(6):265–276. 10.23822/EurAnnACI.1764-1489.207

7. Caiado J, Bras R, Paulino M, Costa L, Castells M. Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic: outcomes and risk factors. Ann Allergy Asthma Immunol. 2020;125(3):325–333.e1. 10.1016/j.anai.2020.04.017

8. Kang Y, Kwon OY, Jung H, Kang M, An J, Lee JH, et al. Breakthrough reactions during rapid drug desensitization: clinical outcome and risk factors. Ann Allergy Asthma Immunol. 2019;123(1):48–56.e1. 10.1016/j.anai.2019.05.007

9. Kim HH, Seo J, Ahn YH, Kim H, Yoon JE, Suh JH, et al. Analysis of breakthrough reactions in 1,143 desensitization procedures in a single tertiary hospital using a one-bag desensitization protocol. Front Allergy. 2022;3:786822. 10.3389/falgy.2022.786822

10. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005;99(2):393–399. 10.1016/j.ygyno.2005.06.028

11. Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract. 2016;4(3):497–504. 10.1016/j.jaip.2015.12.019

12. Chung SJ, Kang SY, Kang RY, Kim YC, Lee KH, Kim TY, et al. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity. Cancer Chemother Pharmacol. 2018;82(5):777–785. 10.1007/s00280-018-3662-0

13. Gorgulu Akin B, Erkoc M, Korkmaz ET, Ozdel Ozturk B, Colak S, Ozalp Ates FS, et al. Rapid drug desensitization with platin-based chemotherapy: analysis of risk factors for breakthrough reactions. World Allergy Organ J. 2022;15(1):100619. 10.1016/j.waojou.2021.100619

14. Madrigal-Burgaleta R, Bernal-Rubio L, Berges-Gimeno MP, Carpio-Escalona LV, Gehlhaar P, Alvarez-Cuesta E. A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to-antineoplastic and biological agents. J Allergy Clin Immunol Pract. 2019;7(2):618–632. 10.1016/j.jaip.2018.07.031

15. Mawhirt SL, Fonacier LS, Calixte R, Davis-Lorton M, Aquino MR. Skin testing and desensitization outcomes among platinum-sensitive oncology patients. Ann Allergy Asthma Immunol. 2018;120(4):437–439. 10.1016/j.anai.2018.01.008

16. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114(2):371–376. 10.1016/j.jaci.2004.04.029

17. Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol. 2007;119(3):726–730. 10.1016/j.jaci.2006.11.640

18. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122(3):574–580. 10.1016/j.jaci.2008.02.044

19. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical-presentation and management. J Allergy Clin Immunol. 2009;123(6):1262–1267.e1. 10.1016/j.jaci.2009.02.042

20. Patil SU, Long AA, Ling M, Wilson MT, Hesterberg P, Wong JT, et al. A protocol for risk stratification of patients with-carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol. 2012;129(2):443–447. 10.1016/j.jaci.2011.10.010

21. Pagani M, Bavbek S, Alvarez-Cuesta E, Berna Dursun A, Bonadonna P, Castells M, et al. Hypersensitivity reactions to chemotherapy: an EAACI position paper. Allergy. 2022;77(2):388–403. 10.1111/all.15113

22. Wang AL, Patil SU, Long AA, Banerji A. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy. Ann Allergy Asthma Immunol. 2015;115(5):422–428. 10.1016/j.anai.2015.07.017

23. Caiado J, Castells MC. Drug desensitizations for chemotherapy: Safety and efficacy in preventing anaphylaxis. Curr Allergy Asthma Rep. 2021;21(6):37. 10.1007/s11882-021-01014-x

24. Tsao LR, Young FD, Otani IM, Castells MC. Hypersensitivity reactions to platinum agents and taxanes. Clin Rev Allergy Immunol. 2022;62(3):432–448. 10.1007/s12016-021-08877-y

25. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17(4):1141. 10.1200/JCO.1999.17.4.1141

26. Banerji A, Lax T, Guyer A, Hurwitz S, Camargo CAJr., Long AA. Management of hypersensitivity reactions to carboplatin and paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract. 2014;2(4):428–433. 10.1016/j.jaip.2014.04.010

27. Otani IM, Wong J, Banerji A. Platinum chemotherapy hypersensitivity: prevalence and management. Immunol Allergy Clin North Am. 2017;37(4):663–677. 10.1016/j.iac.2017.06.003

28. Pradelli J, Verdoire P, Boutros J, Frin AC, Follana P, Duquesne J, et al. Allergy evaluation of hypersensitivity to platinum salts and taxanes: a six-year experience. J Allergy Clin Immunol Pract. 2020;8(5):1658–1664. 10.1016/j.jaip.2019.12.032

29. Otani IM, Castells M. Novel roles for platinum and taxane agent skin testing in risk stratification of chemotherapy hypersensitivity. J Allergy Clin Immunol Pract. 2020;8(5):1665–1667. 10.1016/j.jaip.2020.02.008